Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Shares Outstanding (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Shares Outstanding over the past 3 years, most recently at $12.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $12.8 million for Q4 2025, up 191.57% from a year ago — trailing twelve months through Dec 2025 was $12.8 million (up 191.57% YoY), and the annual figure for FY2025 was $12.8 million, up 191.57%.
  • Shares Outstanding for Q4 2025 was $12.8 million at Tonix Pharmaceuticals Holding, up from $10.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for TNXP hit a ceiling of $12.8 million in Q4 2025 and a floor of $20926.0 in Q4 2023.
  • Median Shares Outstanding over the past 3 years was $1.2 million (2023), compared with a mean of $3.8 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 95.48% in 2024 and later skyrocketed 26716.19% in 2025.
  • Tonix Pharmaceuticals Holding's Shares Outstanding stood at $20926.0 in 2023, then soared by 20859.23% to $4.4 million in 2024, then skyrocketed by 191.57% to $12.8 million in 2025.
  • The last three reported values for Shares Outstanding were $12.8 million (Q4 2025), $10.2 million (Q3 2025), and $7.5 million (Q2 2025) per Business Quant data.